Sign-up-button1







Categorie: Emerging Markets
Submitted 6 months ago by Netaug01_25_tiny Drdutta contact me
After days of speculation and denials , Ranbaxy Laboratories and Orchid chemicals finally announced an alliance "involving multiple geographies and therapies for both finished dosage formulations and active pharmaceutical ingredients." But what does this agreement actually mean on the ground?In my opinion, deal unites Orchid’s manufacturing capabilities in Cephalosporins (a new generation of antibiotics) and Carbapenems (antibiotics administered intravenously in hospitals for serious infections) with Ranbaxy’s marketing prowess and wide geographical reach. Orchid has FDA certified manufacturing plants in addition to a wide range of product offerings in Cephalosporins and Carbapenems, but it lacks the front-end to market them. This is exactly where Ranbaxy scores—over the years, it has invested heavily to build a marketing and distribution network across geographies. This is why the alliance is good for both firms.</p... More...

0 comments ↓




Please Login or Register to comment

India economy emerging markets Pakistan reliance BHEL power fund banks Asia IT mortgage housing bank siemens US GOOG telecommunications educational baidu bidu Pharmaceutical Biotech Investing in Sin Obesity Diabetes Novo Nordisk Reliance Infratel IPO FIIs Stock Investing Trading Sensex Mutual Funds Deciem in AUM emerging market Funds Tractors Autos vehicles Review Financial Millat limited expansion Software company IT company UAE Petrobras PBR Brazil Oil wireless technology AMX VIP VSL Private Sector ICICI bank Vs Rest

More Tags